HQL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 11:46):

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe...

Stats
Today's Volume	75 296.00
Average Volume	110 414
Market Cap	335.01M
Last Dividend	$0.300 ( 2023-11-21 )
Next Dividend	$0 ( N/A )
P/E	16.18
ATR14	$0.00900 (0.07%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-09	Goetz Kathleen	Buy	400	Common Stock
2024-03-13	Tse Loretta	Buy	0
2024-01-02	Reit Todd	Buy	1 000	Common Stock
2023-12-28	Maher Bill	Buy	1 000	Common Stock
2023-12-13	Duitz Joshua	Buy	0

INSIDER POWER
100.00
Last 50 transactions
Buy: 125 021 \| Sell: 55 759

Volume Correlation

Long: -0.17 (neutral)

Short: 0.58 (weak)

Signal:(31.373) Neutral

Tekla Life Sciences Correlation

10 Most Positive Correlations
FPI	0.888
TSN	0.883
ASH	0.878
DHX	0.878
AMRC	0.874
DVN	0.873
CWT	0.871
PDS	0.868
CVX	0.867
EBR-B	0.864

10 Most Negative Correlations
VCRA	-0.862
AMAM	-0.861
COR	-0.86
SCX	-0.856
IOT	-0.853
NGL	-0.845
FPAC-UN	-0.845
MOG-B	-0.842
TNK	-0.835
TK	-0.831

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Tekla Life Sciences Correlation - Currency/Commodity

0.11
( neutral )

-0.11
( neutral )

0.00
( neutral )

-0.42
( neutral )

Tekla Life Sciences Financials

Annual	2023
Revenue:	$23.52M
Gross Profit:	$18.28M (77.71 %)
EPS:	$0.830

Q4	2023
Revenue:	$29.56M
Gross Profit:	$26.97M (91.24 %)
EPS:	$-0.430

Q2	2023
Revenue:	$9.82M
Gross Profit:	$7.17M (72.98 %)
EPS:	$1.290

Q1	2023
Revenue:	$964 636
Gross Profit:	$964 636 (100.00 %)
EPS:	$0.640

Financial Reports:

No articles found.

Tekla Life Sciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.310 (N/A)	$0.310 (N/A)	$0.330 (N/A)	$0.320 (N/A)	$0.320 (N/A)	$0.300 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Tekla Life Sciences Dividend Information - Dividend King

Dividend Sustainability Score: 1.137 - low (50.00%) | Divividend Growth Potential Score: 1.124 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$1.640	1996-11-14
Last Dividend	$0.300	2023-11-21
Next Dividend	$0	N/A
Payout Date	2024-01-10
Next Payout Date	N/A
# dividends	99	--
Total Paid Out	$43.17	--
Avg. Dividend % Per Year	5.54%	--
Score	5.04	--
Div. Sustainability Score	1.137
Div.Growth Potential Score	1.124
Div. Directional Score	1.131	--

Next Divdend (Est)
(2024-05-06)

$0.326 Estimate 38.53 %

Dividend Stability

0.77 Good

Dividend Score

5.04

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1996	$1.640	10.80%
1997	$0.740	5.38%
1998	$0.360	2.76%
1999	$1.110	9.06%
2000	$4.16	20.50%
2001	$3.14	14.90%
2002	$2.18	10.20%
2003	$1.240	10.10%
2004	$1.365	8.62%
2005	$2.06	13.00%
2006	$1.240	7.90%
2007	$1.170	8.74%
2008	$1.100	8.33%
2009	$0.420	4.59%
2010	$0.520	5.46%
2011	$1.010	9.29%
2012	$1.160	10.00%
2013	$1.390	9.19%
2014	$1.770	8.72%
2015	$2.80	11.20%
2016	$2.07	8.99%
2017	$1.620	9.38%
2018	$1.620	8.18%
2019	$1.400	9.03%
2020	$1.560	8.98%
2021	$1.690	8.71%
2022	$1.360	7.05%
2023	$1.270	8.87%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.973	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0975	1.200	6.75	8.10	[0 - 0.3]
returnOnEquityTTM	0.0944	1.500	-0.0620	-0.0930	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0	2.00	0	0	[0 - 30]
freeCashFlowPerShareTTM	0	2.00	0	0	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.870	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.542	1.000	1.153	1.153	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.100	0.800	-2.67	-2.13	[0.5 - 2]
Total Score				1.137

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	9.00	1.000	9.19	0	[1 - 100]
returnOnEquityTTM	0.0944	2.50	-0.0399	-0.0930	[0.1 - 1.5]
freeCashFlowPerShareTTM	0	2.00	0	0	[0 - 30]
dividendYielPercentageTTM	10.08	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0	2.00	0	0	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.0356	1.500	-3.57	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				1.124

Tekla Life Sciences

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.